236 related articles for article (PubMed ID: 37025940)
1. Cardiovascular Risk in Transgender People With Gender-Affirming Hormone Treatment.
Masumori N; Nakatsuka M
Circ Rep; 2023 Apr; 5(4):105-113. PubMed ID: 37025940
[TBL] [Abstract][Full Text] [Related]
2. Gender-affirming estrogen therapy route of administration and cardiovascular risk: a systematic review and narrative synthesis.
Turino Miranda K; Kalenga CZ; Saad N; Dumanski SM; Collister D; Rytz CL; Lorenzetti DL; Chang DH; McClurg C; Sola DY; Ahmed SB
Am J Physiol Heart Circ Physiol; 2022 Nov; 323(5):H861-H868. PubMed ID: 36053748
[TBL] [Abstract][Full Text] [Related]
3. Effects of gender-affirming hormone therapy on insulin resistance and body composition in transgender individuals: A systematic review.
Spanos C; Bretherton I; Zajac JD; Cheung AS
World J Diabetes; 2020 Mar; 11(3):66-77. PubMed ID: 32180895
[TBL] [Abstract][Full Text] [Related]
4. Gender-Affirming Hormone Therapy, Vascular Health and Cardiovascular Disease in Transgender Adults.
Connelly PJ; Marie Freel E; Perry C; Ewan J; Touyz RM; Currie G; Delles C
Hypertension; 2019 Dec; 74(6):1266-1274. PubMed ID: 31656099
[TBL] [Abstract][Full Text] [Related]
5. [Hormone treatment of transgender people: Long-term health effects and safety].
de Blok CJM; Wiepjes CM; Nota NM; den Heijer M
Ned Tijdschr Geneeskd; 2020 Jul; 164():. PubMed ID: 32757514
[TBL] [Abstract][Full Text] [Related]
6. The Desire and Status of Gender-Affirming Hormone Therapy and Surgery in Transgender Men and Women in China: A National Population Study.
Liu Y; Xin Y; Qi J; Wang H; Hong T; Yang X; Li B; Chang X; Knudson G; Zhao Z; Pan B
J Sex Med; 2020 Nov; 17(11):2291-2298. PubMed ID: 32868262
[TBL] [Abstract][Full Text] [Related]
7. Effects of Gender-Affirming Hormones on Lipid, Metabolic, and Cardiac Surrogate Blood Markers in Transgender Persons.
Defreyne J; Van de Bruaene LDL; Rietzschel E; Van Schuylenbergh J; T'Sjoen GGR
Clin Chem; 2019 Jan; 65(1):119-134. PubMed ID: 30602477
[TBL] [Abstract][Full Text] [Related]
8. What is the most anticipated change induced by treatment using gender-affirming hormones in individuals with gender incongruence?
Masumori N; Baba T; Abe T; Niwa K
Int J Urol; 2021 May; 28(5):526-529. PubMed ID: 33465834
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Gender-Affirming Hormone Therapy and Cognitive Functioning in Older Transgender Women Compared With Cisgender Women and Men.
van Heesewijk JO; Dreijerink KMA; Wiepjes CM; Kok AAL; van Schoor NM; Huisman M; den Heijer M; Kreukels BPC
J Sex Med; 2021 Aug; 18(8):1434-1443. PubMed ID: 34247950
[TBL] [Abstract][Full Text] [Related]
10. Mapping evidence on the effects of gender-affirming hormone therapy on the hard and soft tissues of the craniofacial complex in transgender people: a protocol for a scoping review.
Van den Bosch MF; Wiepjes CM; Den Heijer M; Schoonmade LJ; Jonkman REG; Meursinge Reynders RA
Syst Rev; 2021 Apr; 10(1):109. PubMed ID: 33853686
[TBL] [Abstract][Full Text] [Related]
11. Transgender health and the impact of aging and menopause.
Cheung AS; Nolan BJ; Zwickl S
Climacteric; 2023 Jun; 26(3):256-262. PubMed ID: 37011669
[TBL] [Abstract][Full Text] [Related]
12. Gender-affirming hormones and surgery in transgender children and adolescents.
Mahfouda S; Moore JK; Siafarikas A; Hewitt T; Ganti U; Lin A; Zepf FD
Lancet Diabetes Endocrinol; 2019 Jun; 7(6):484-498. PubMed ID: 30528161
[TBL] [Abstract][Full Text] [Related]
13. Risk of Venous Thromboembolism in Transgender People Undergoing Hormone Feminizing Therapy: A Prevalence Meta-Analysis and Meta-Regression Study.
Totaro M; Palazzi S; Castellini C; Parisi A; D'Amato F; Tienforti D; Baroni MG; Francavilla S; Barbonetti A
Front Endocrinol (Lausanne); 2021; 12():741866. PubMed ID: 34880832
[TBL] [Abstract][Full Text] [Related]
14. Providing Care for Transgender Persons With Kidney Disease: A Narrative Review.
Collister D; Saad N; Christie E; Ahmed S
Can J Kidney Health Dis; 2021; 8():2054358120985379. PubMed ID: 33552529
[TBL] [Abstract][Full Text] [Related]
15. Effect of cross-sex hormones on the quality of life, depression and anxiety of transgender individuals: a quantitative systematic review.
Rowniak S; Bolt L; Sharifi C
JBI Database System Rev Implement Rep; 2019 Sep; 17(9):1826-1854. PubMed ID: 31021971
[TBL] [Abstract][Full Text] [Related]
16. Sexual Desire Changes in Transgender Individuals Upon Initiation of Hormone Treatment: Results From the Longitudinal European Network for the Investigation of Gender Incongruence.
Defreyne J; Elaut E; Kreukels B; Fisher AD; Castellini G; Staphorsius A; Den Heijer M; Heylens G; T'Sjoen G
J Sex Med; 2020 Apr; 17(4):812-825. PubMed ID: 32008926
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular implications of gender-affirming hormone treatment in the transgender population.
Dutra E; Lee J; Torbati T; Garcia M; Merz CNB; Shufelt C
Maturitas; 2019 Nov; 129():45-49. PubMed ID: 31547912
[TBL] [Abstract][Full Text] [Related]
18. SERUM HORMONE CONCENTRATIONS IN TRANSGENDER INDIVIDUALS RECEIVING GENDER-AFFIRMING HORMONE THERAPY: A LONGITUDINAL RETROSPECTIVE COHORT STUDY.
Chantrapanichkul P; Stevenson MO; Suppakitjanusant P; Goodman M; Tangpricha V
Endocr Pract; 2021 Jan; 27(1):27-33. PubMed ID: 33471729
[TBL] [Abstract][Full Text] [Related]
19. Continuation of gender-affirming hormones in transgender people starting puberty suppression in adolescence: a cohort study in the Netherlands.
van der Loos MATC; Hannema SE; Klink DT; den Heijer M; Wiepjes CM
Lancet Child Adolesc Health; 2022 Dec; 6(12):869-875. PubMed ID: 36273487
[TBL] [Abstract][Full Text] [Related]
20. Transgender Medicine and Risk of Venous Thromboembolism.
Bunderen CCV; Leentjens J; Middeldorp S
Hamostaseologie; 2022 Oct; 42(5):301-307. PubMed ID: 36323277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
